PCA3 and pachyonychia congenita: An enhanced predictive value and a more accurate diagnosis for PC have been suggested through the identification of novel biomarkers like prostate cancer antigen 3 (PCA3) and transmembrane protease serine 2 ETS-related gene (TMPRSS2-ERG) among several others [11].